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ABSTRACT Streptococcus pneumoniae causes a high burden of invasive pneumococcal disease (IPD) globally, especially in chil-
dren from resource-poor settings. Like many bacteria, the pneumococcus can import DNA from other strains or even species by
transformation and homologous recombination, which has allowed the pneumococcus to evade clinical interventions such as
antibiotics and pneumococcal conjugate vaccines (PCVs). Pneumococci are enclosed in a complex polysaccharide capsule that
determines the serotype; the capsule varies in size and is associated with properties including carriage prevalence and virulence.
We determined and quantified the association between capsule and recombination events using genomic data from a diverse
collection of serotypes sampled inMalawi. We determined both the amount of variation introduced by recombination relative to
mutation (the relative rate) and howmany individual recombination events occur per isolate (the frequency). Using univariate
analyses, we found an association between both recombinationmeasures andmultiple factors associated with the capsule, in-
cluding duration and prevalence of carriage. Because many capsular factors are correlated, we used multivariate analysis to cor-
rect for collinearity. Capsule size and carriage duration remained positively associated with recombination, although with a re-
duced P value, and this effect may be mediated through some unassayed additional property associated with larger capsules.
This work describes an important impact of serotype on recombination that has been previously overlooked.While the details of
how this effect is achieved remain to be determined, it may have important consequences for the serotype-specific response to
vaccines and other interventions.
IMPORTANCE The capsule determines>90 different pneumococcal serotypes, which vary in capsule size, virulence, duration,
and prevalence of carriage. Current serotype-specific vaccines elicit anticapsule antibodies. Pneumococcus can take up exoge-
nous DNA by transformation and insert it into its chromosome by homologous recombination. This mechanism has dissemi-
nated drug resistance and generated vaccine escape variants. It is hence crucial to pneumococcal evolutionary response to inter-
ventions, but there has been no systematic study quantifying whether serotypes vary in recombination and whether this is
associated with serotype-specific properties such as capsule size or carriage duration. Larger capsules could physically inhibit
DNA uptake, or given the longer carriage duration for larger capsules, this may promote recombination.We find that recombi-
nation varies among capsules and is associated with capsule size, carriage duration, and carriage prevalence and negatively asso-
ciated with invasiveness. The consequence of this work is that serotypes with different capsules may respond differently to selec-
tive pressures like vaccines.
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The global mortality due to invasive pneumococcal disease(IPD) has been estimated at more than 1 million per annum,
with the majority of deaths occurring in children less than 5 years
old (1). Use of a 7-valent pneumococcal conjugate vaccine
(PCV7) and subsequent 13-valent (PCV13) formulations has
been followed by a precipitate reduction in IPD due to vaccine
serotypes (VTs) in the United States, including a substantial herd
effect in unvaccinated individuals (2, 3). PCVs are plainly an ef-
fective selective pressure on the pneumococcal population. The
response to that pressure has been notable for the increase in prev-
alence of nonvaccine serotypes (NVTs). More than 90 distinct
serotypes have been described (410), so even PCV13 protects
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against a small minority of antigenic diversity in this organism.
Following vaccination, the prevalence of NVTs in carriage, and to
a lesser extent in IPD, has increased as the NVTs took advantage of
the removal of their competitors in a process termed serotype
replacement (1113). An important component of serotype re-
placement has been the success of “capsule switch” vaccine escape
variants (14). These variants are lineages that were previously as-
sociated with a vaccine serotype but have persisted in the postvac-
cine environment by the introduction of genes for an NVT capsule
through homologous recombination (15). The known ability of
the pneumococcus to undergo homologous recombination has
also been associated with the acquisition of drug resistance (16,
17) and numerous examples of capsule switch variants (15,
1820). As a result of this recombination-mediated shuffling of
serotype and genotype, when PCVs were introduced, the popula-
tion already contained potential vaccine escape variants, some of
which have subsequently become common and important causes
of disease.
The polysaccharide capsule is known to influence multiple as-
pects of pneumococcal biology. Serotypes vary in their nasopha-
ryngeal carriage rates (21), and their propensity to cause IPD was
usually expressed as the “invasive potential” in order to account
for the various exposures to different serotypes (2224). More-
over, these properties have been linked to basic biochemical fea-
tures of the capsule: those capsules with fewer carbons in the re-
peat unit of the polysaccharide tend to be thicker and exhibit a
more negative surface charge (25) and are associated with a longer
duration of carriage and a higher carriage prevalence—an out-
come that may be linked to enhanced resistance to opsonophago-
cytic killing (21). Those serotypes more associated with virulence
meanwhile, tend to have smaller capsules and shorter durations of
carriage (21, 22, 24).
Despite the importance of both recombination and capsule to
pneumococcal biology, whether serotypes vary in their recombi-
nation rates in nature and what drives it have not been extensively
studied. Genomic studies have shown that different pneumococ-
cal lineages plainly vary in the amount that recombination has
contributed to their diversification (20, 26) but have not linked
this to the different serotypes associated with each lineage. These
studies have also suggested that lineages that completely lack cap-
sule may have a higher relative rate of recombination, suggesting
that the capsule can impede the uptake of DNA (26). Support for
this comes from the observation that mechanisms such as biofilm
formation and downregulation of capsule biosynthesis have been
reported to facilitate DNA uptake and chromosomal integration
in vitro (27). This finding suggested that the polysaccharide cap-
sule may inhibit genetic exchange in encapsulated isolates either
physically or structurally (28).
There are hence potentially antagonistic roles for serotype in
recombination. A larger capsule is associated with a higher prev-
alence and longer duration of carriage, therefore offering more
opportunities to undergo recombination, but conversely, experi-
mental and observational data suggest that the absence of capsule
increases transformation and recombination (26, 27). As yet,
there has been no attempt to quantify the association between
serotype properties, such as capsule size and carriage duration,
and the amount of recombination that those serotypes experience.
Understanding this is important because as noted, recombination
is crucial to the response of pneumococci to medical interventions
(19), and if serotypes vary in recombination in a predictable fash-
ion, we might be able to predict those that are a higher risk of
developing drug resistance or vaccine escape.
In the present study, we used whole genomes of 439 pneumo-
coccal isolates collected in Malawi, a low-income country in sub-
Saharan Africa with high pneumococcal carriage rates (29) and
which contains a wide range of serotypes, including serotypes with
very low prevalence or that are absent in industrialized countries
such as serotype 1 and 5 (18). We quantified the extent to which
recombination has contributed to the history of serotype-specific
lineages and combined this with data on carriage duration, inva-
sive potential, carriage prevalence, and capsule size to quantita-
tively investigate the association. Our results demonstrate signif-
icant associations between the recombination rate and frequency
with the carriage duration, invasive potential, and size of the outer
cell wall polysaccharide capsule in pneumococcal isolates.
RESULTS
We sequenced the genomes of 439 Streptococcus pneumoniae clin-
ical isolates collected from the Queen Elizabeth Central Hospital
(QECH) in Blantyre, Malawi (southeastern Africa), between 2002
and 2010. The set of samples comprised 364 invasive isolates and
75 carriage isolates and representatives of 48 distinct serotypes.
The most common serotypes were serotype 1 with 83 isolates (52
isolates from blood, 28 isolates from cerebral spinal fluid [CSF],
and 3 isolates from carriers), serogroup 6 with 46 isolates (25
isolates from blood, 11 isolates from CSF, and 10 isolates from
carriers), serotype 5 with 25 isolates (17 isolates from blood, 6
isolates from CSF, and 2 isolates from carriers), and other sero-
types (285 isolates; 126 isolates from blood, 99 isolates from CSF,
and 60 isolates from carriers) (see Table S1 in the supplemental
material). Whole-genome sequencing was done using the HiSeq
platform (Illumina, CA, USA) as described in Materials and Meth-
ods. The raw sequence reads had an average length of 72.23 bp
(95% confidence interval [95% CI], 70.58 to 73.87 bp), average
read quality of 33.48 (95% CI, 33.22 to 33.75), and average insert
size of 263.30 kb (95% CI, 263.3 to 270.10 kb) per genome
(Fig. S1). Consensus de novo sequence assemblies were generated
(30, 31) with an average of 66.43 contigs (95% CI, 63.65 to 69.22)
and an average chromosome size of 2.09 Mb (95% CI, 2.09 to
2.10 Mb) and average contig size of 37.31 kb (95% CI, 35.91 to
38.72 kb) per genome. The phylogeny of all the isolates was con-
structed using a 0.79-Mb multiple-sequence alignment of 852
concatenated core genes containing 51,389 single nucleotide poly-
morphisms (SNPs) (32). For the analysis of serotype-specific evo-
lution of lineages identified as described below, SNPs were called
against reference genomes (Table S2).
Population structure. Analysis of the population using BAPS
(33, 34) identified 14 primary sequence clusters (SCs) (Fig. 1). Of
these 14 SCs, SC1 to SC13 were monophyletic clades. The remain-
ing SC, SC14, contained sequences that could not be assigned to a
monophyletic SC, and the streptococci in this polyphyletic SC are
a diverse group of rare lineages, the grouping of which does not
necessarily reflect common evolutionary history, and hence, we
undertake no further analysis of this group. Most SCs contained
isolates with a single serotype and multiple closely related se-
quence types (STs) as determined by multilocus sequence typing
(MLST) (Fig. 1; see Table S1 in the supplemental material). In
some cases, SCs contained multiple serotypes separated by long
branches. A notable example is SC9, which consisted of clearly
distinct subclades of serotype 6A and 35B (Fig. 1), which we split
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into two subclades 6A-SC9 and 35B-SC9 for the serotype-specific
analyses. The subclade with serotype 35B in SC9 contained addi-
tional serotypes with the same ST that were extremely closely re-
lated at the whole-genome level (Fig. 1), which suggests that this
subclade was a single lineage of serotype 35B that recently ac-
quired other capsule types.
Variation in recombination among serotypes. Pneumococci
are known to undergo homologous recombination, and all SCs
containing capsule switch variants reflect a history of homologous
recombination events. To determine the specific recombination
events responsible for these changes, as well as those that could
have occurred elsewhere in the genome, we used Gubbins (35),
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FIG 1 Population structure of S. pneumoniae strains from carriers and patients with invasive disease. The phylogeny was constructed using a 0.79-Mb
multiple-sequence alignment with 51,389 SNPs from 852 universally conserved (core) genes present in single copies. The 14 sequence clusters (SCs) identified
by BAPS are labeled on the edge of the phylogeny. Clades corresponding to the 13 different monophyletic SCs (SC1 to SC13) are shown in different colors, while
clades for all the strains in the polyphyletic clade (SC14) comprising of the “unclustered” sequences are not colored. The outermost ring around the phylogeny
shows whether a serotype is a vaccine type (VT) included in the PCV13 pneumococcal vaccine formulation (black) or nonvaccine type (NVT) not included
(white). Phylogeny was rooted using an outgroup method on a branch containing nontypeable (NT) pneumococci, which are genetically distinct from all
pneumococcal strains.
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which identifies regions with an atypically high density of SNPs
using a sliding window approach (Fig. 2a and b; see Fig. S3a to S3o
in the supplemental material). We distinguish between two sepa-
rate recombination parameters. The relative recombination rate
(r/m) is the ratio of the numbers of SNPs introduced by recom-
bination to the number introduced by mutation. It hence mea-
sures the total amount of diversity accumulated by a lineage. In
contrast, the recombination frequency (re) is defined as the av-
erage number of recombination events inferred per isolate, re-
gardless of how much variation they have introduced. Hence, a
large amount of recombination with closely related strains could
lead to a high re but a low r/m. Furthermore, higher presence of
shared ancestral recombination events acquired through clonal
descent than strain-specific events introduced independently may
lead to a high re. The averages of both these parameters were
calculated for each SC. While SC1 and SC2 both contained isolates
with a single serotype (serotype 1 and 5, respectively), in the case
of SCs containing more than one serotype, the statistics for each
were calculated independently (Table 1). Separate estimates were
obtained for the two distinct 6A clades in SC3 and SC9, which we
refer to as 6A-SC3 and 6A-SC9, respectively, on the basis of the
predominant STs in each.
Estimates ofr/m ranged from 0.44 to 23.45 with a mean of 8.89
(95% CI, 5.243 to 12.43) (Table 1), and the only estimate less than
1 was found in the 16F lineage SC5. The highest values ofr/m were
12.53 for serotypes 23F-SC8, 23.45 for 6A-SC3, 12.85 for 6A-SC9,
and 17.02 for 35B-SC9, while serotypes 1-SC2 (r/m 2.61), 16F-
SC5 (r/m 0.44), 4-SC13 (r/m 1.67), and 5-SC1 (r/m 2.82)
showed the lowest values (Table 1). The distribution ofr/m values
deviated from a normal distribution (P 0.0001) on the basis of
three normality tests (see Materials and Methods). In serotypes of
the same SC, such as 35B, 6A, and 18B/C in SC4, SC9, and SC13,
respectively, the distribution of r/m ratios per branch were not
different with P values of 0.7431 and 0.9350, respectively. The
average estimated re was 6.316 (95% CI, 3.316 to 9.316) and
ranged from 0.11 to 20.08. The highest re estimates were 12.26
for 23F-SC8, 20.08 for 35B-SC9, 8.91 for 6A-SC3, and 11.92 for
6A-SC9, while serotypes 1-SC2 (re  0.73), 16F-SC5 (re 
0.11), 4-SC13 (re 0.75), and 5-SC1 (re 2) showed the lowest
re values (Table 1). Significant differences (P  0.0005) in the
average numbers of recombination events in each serotype were
also observed by using the same test (see Fig. S2b in the supple-
mental material). The Kruskal-Wallis test was used because of
significant deviations of the distributions of both r/m per branch
in each serotype and the average number of recombination events
for each serotype from the normal distribution. Interestingly,
both distinct lineages with 6A capsule type consistently showed
highr/m (23.45 in SC3 and 12.85 in SC9) andre (8.91 in SC3 and
11.92 in SC9) despite having a dissimilar genetic backbone. In
addition, r/m positively correlated with re (R2  0.5168; P 
0.0025) (Fig. 3). The pneumococcal pherotypes or competence-
stimulating peptides (CSP) encoded by the comC gene were di-
verse and variably distributed in the SCs but showed no obvious
association with the recombination parameters (Table 1).
Serotype-specific carriageduration, prevalence, and invasive
potential correlatewith recombination.Different pneumococcal
lineages vary in the extent of recombination that has influenced
their genomes (20, 26). Serotypes are known to vary in their du-
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FIG 2 Recombination inferred by Gubbins. Recombination events mapped onto internal nodes (red blocks) and terminal branches (blue blocks) are illustrated
for a typical low-recombination serotype (serotype 1 [SC1]) (a) and a high-recombination serotype (serotype 6A [SC3]) (b). (i) Maximum likelihood phyloge-
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the reference S. pneumoniae genome showing all the genetic annotations and locations of some well-known genes. (iii) Matrix showing the tracks representing
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strains that contain them. Recombination events in internal branches (red) were present in multiple isolates and were shared through clonal descent rather than
independent acquisitions, while those in the terminal branches (blue) were isolate specific and represent independent recent acquisitions. The recombination
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ration of carriage and propensity to cause invasive disease per
exposure. A longer duration of carriage could offer more oppor-
tunities for cocolonization with different strains and possible re-
combination. We hence tested the association for each serotype
between r/m and re and previously published serotype-specific
estimates of carriage duration (36), carriage prevalence data from
this study, capsule size (21), and invasive potential (defined as the
odds ratio for causing invasive disease to carriage [ICOR] [22, 37])
using univariate linear regression. We observed a positive associ-
ation between bothr/m (R2 0.4664; P 0.0071) andre (R2
0.3393; P  0.0367) with carriage duration (Fig. 4a and Table 2;
see Fig. S4a in the supplemental material), but onlyr/m showed a
significant association (R2  0.4173; P  0.0093) with carriage
prevalence of the serotypes (Table 2; see Fig. S6a and S6b in the
supplemental material). When modeling the relationship between
carriage duration and re, serotype 35B-SC9 was excluded as an
outlier, but its inclusion decreased the P value (R2 0.2406; P
0.0749). Both r/m (R2  0.4549; P  0.0228) and re (R2 
0.7155; P 0.0010) showed negative association with the invasive
potential of the studied serotypes (Fig. 4b and Table 2; Fig. S4b and
S4c). In multivariable regression, the association of carriage dura-
tion, prevalence, and invasive potential disappeared (Table 2).
Repeated univariate and multivariate analyses using only those
serotypes for which all response variables were available found
similar results (Table S3). A multivariate regression to account for
this removed the significant association with serotype invasive
potential, while the association with carriage duration and capsule
size remained (Table 2).
Recombination correlates with larger polysaccharide cap-
sules. Capsule size has been associated with the factors described
above—the serotype-specific duration of carriage and prevalence.
The polysaccharide capsule size data for different pneumococcal
serotypes, determined by the fluorescein isothiocyanate-labeled
dextran (FITC-dextran) assay, were obtained from Weinberger
and colleagues (21). By using univariate regression, we observed
positive association between the capsule size andre (R2 0.5892;
P  0.0095), but not r/m (R2  0.1186; P  0.300) (Fig. 5; Ta-
ble 2). Excluding serotype 35-SC9, which was deemed to be an
outlier observation, the linear association between capsule size
and r/m increased (R2 0.3519; P 0.0544). This was robust to
multivariate analysis (P  0.0296). We also did a multivariable
regression to account for collinearity among capsule size, duration
of carriage, carriage prevalence, and invasive potential and iden-
tify the independent contribution of each, which showed no asso-
ciation between r/m and re (Table 2; see Table S3 in the supple-
mental material).
DISCUSSION
Recombination is a fundamental process in the evolution and ad-
aptation of many pathogens. It is capable of shuffling existing
TABLE 1 Summary statistics for the genetic recombination events identified in each serotype
Serotype
Sequence
cluster
(SC)
No. of
isolates
(n)
Mean no. of
recombination
events/isolate (re)
Mean recombination to mutation (r/m) Recombination size (bp) Pherotypea
Mean 95% CIb Mean 95% CI CSP1 CSP2 Other
5 SC1 25 2 2.82 0.295.35 7,642 3,87711,407 100 0 0
1 SC2 83 0.73 2.61 0.744.48 8,727 5,75311,702 98.78 0 1.22
6A SC3 11 8.91 23.45 1.5445.44 11,579 8,87214,286 0 100 0
19A SC4 12 5.58 11.26 4.6417.89 9,143 6,30811,979 0 0 100
16F SC5 9 0.11 0.44 01.39 36,616 0 0 0 100
3 SC6 10 8.1 9.45 023.53 8,020 6,2019,839 0 0 100
10B SC7 14 2.07 4.15 08.70 9,855 4,80514,905 76.47 17.65 5.88
23F SC8 19 12.26 12.53 7.3317.72 8,094 6,7379,451 94.74 0 5.26
35B SC9 13 20.08 17.02 5.3128.74 9,022 7,98710,056 100 0 0
6A SC9 12 11.92 12.85 4.5521.15 7,115 5,6978,532 100 0 0
12F SC10 19 5.16 8.17 2.3813.97 7,709 6,0169,401 94.74 0 5.26
7A/F SC11 20 6.4 8.74 3.0914.38 6,924 5,5478,302 95 0 5
14 SC12 15 4 13.93 4.7023.16 6,745 4,9268,563 100 0 0
18B/C SC13 8 6.67 3.49 011.15 9,469 6,21512,724 83.78 16.22 0
4 SC13 6 0.75 1.67 03.67 9,208 020,175 38.75 32.56 28.29
a Proportion of the pneumococcal pherotypes or competence-stimulating peptide (CSP) encoded by the comC gene and its variants in each SC. Detailed information about the
CSPs is shown in Fig. S2c and S2d in the supplemental material.
b 95% CI, 95% confidence interval.
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variation into more fit combinations, and in the case of pneumo-
coccus, it has been an important force in its response to medical
interventions like vaccines and antibiotics (19). Despite the obvi-
ous benefits to the pathogen that recombination offers in this
regard, the rates with which it occurs vary greatly among pneu-
mococcal lineages and serotypes (26) for reasons that are obscure.
Understanding the factors that contribute to this variation is im-
portant as we attempt to limit the potential of pneumococcal evo-
lution to erode the benefits of clinical innovation.
Previous studies have commented on the low presence of re-
combination in certain serotypes, such as the “highly invasive”
serotypes 1 and 7F (20, 38, 39). A systematic comparison of cap-
sular types is challenging because some serotypes are compara-
tively rare or absent from samples taken in industrialized coun-
tries, and while it might be possible to combine studies from
different sites, it would be important to account for any bias aris-
ing from variation in recombination in different regions—for in-
stance, previous work with MLST data found more evidence of
recombination in samples from African carriers and speculated
that this might be the consequence of a higher carriage rate (40).
We have used a set of pneumococcal samples that includes an
unusually wide range of serotypes with diverse properties, and we
found a clear association between serotype and r/m and re. Be-
cause of lack of data in resource-poor settings, we used previously
published data on the properties of serotypes, such as capsule size,
carriage duration, prevalence, and invasive capacity (all of which
vary relatively little among sample sites); we found that all were
associated with one recombination parameter or the other recom-
bination parameter or both. In univariate analysis, a negative as-
sociation with invasive capacity mirrored a positive association of
r/m with carriage duration and prevalence—likely reflecting the
fact that the majority of highly invasive serotypes are also infre-
quently carried. However, it should be noted that we did not have
specific invasiveness data from pneumococci infecting the Malawi
population, and there are few estimates for this quantity from
resource-poor settings, so this is an important focus for future
work.
We have also found more frequent recombination in serotypes
with larger outer cell wall polysaccharide capsules, which shows
that despite the potential physical barrier offered by the capsule,
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TABLE 2 Summarized estimates from the univariate, multivariable, and multivariate multiple regression
Response
variable
Predictor
variable
Univariate Multivariable Multivariate
Estimate SE P valuea Estimate SE P value Estimateb Approx. F P valuea
Recombination
rate (r/m)
Capsule size 0.0205 0.0186 0.3000 0.0185 0.0242 0.487 0.9044 14.183 0.0296*
Carriage duration 0.3336 0.1030 0.0071* 0.2149 0.3301 0.550 0.9085 14.884 0.0277*
Invasive potential 0.7930 0.2894 0.0228* 0.8847 0.7927 0.327 0.4032 1.0134 0.4611
Carriage prevalence 1.0030 0.3287 0.0093* 0.1081 0.9468 0.915 0.5457 1.8021 0.3062
Recombination
frequency (re)
Capsule size 0.0263 0.0078 0.0095* 0.0057 0.0081 0.516 0.9044 14.183 0.0296*
Carriage duration 0.1707 0.0718 0.0367* 0.2595 0.1101 0.078 0.9085 14.884 0.0277*
Invasive potential 0.6142 0.1291 0.0010* 0.4127 0.2645 0.194 0.4032 1.0134 0.4612
Carriage prevalence 0.5443 0.3260 0.1189 0.4967 0.3159 0.191 0.5457 1.8021 0.3062
a The asterisks in the P value columns indicate significant values.
b All test statistics, i.e., Pillai-Bartlett trace criterion, Wilks’ lambda, Hotelling-Lawley trace, and Roy’s greatest root, were used to summarize the results from the multivariate
analysis of variance (MANOVA) of the multivariate multiple regression model. All the tests showed identical P values. For illustration, only estimates using the Pillai-Bartlett trace
are shown.
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the presence of a larger capsule itself does not simply reduce re-
combination. While this could be considered surprising, it is im-
portant to note that serotypes with enlarged capsules are typically
carried for longer duration and resist neutrophil phagocytosis
(21) and complement-mediated immune responses (41, 42) than
serotypes with smaller capsules. In addition, this may be because
some of the serotypes with larger capsules have lower metabolic
costs (21) associated with capsule expression and may have a
higher ability to form biofilms which may prevent elimination
(27). This suggests that longer duration of carriage and lower
clearance rates by the host’s immune system in serotypes with
enlarged capsules leads to sustained exposure to cocolonizers (po-
tential donors of exogenous DNA), which has been previously
described to facilitate recombination (40). This in turn results in
higher recombination than in serotypes with thinner capsules,
which are presented with limited opportunities for recombination
due to rapid clearance. The intrinsic recombination rates in vitro
in the absence of capsule-induced immune clearance may be dif-
ferent than observed in the natural population where various fac-
tors such as strain competition and immune responses can di-
rectly affect the recombination rate. Hence, the results of in vitro
studies may be misleading when applied to the nasopharynx. In
addition, there was no obvious association between the pneumo-
coccal pherotypes such as CSP1, CSP2, and other variants en-
coded by the comC gene and its allelic variants, which suggests that
the observed differences in recombination may not be due to the
differences in competence. The evidence presented here certainly
strongly suggests that capsule does not prevent recombination in
any straightforward fashion. However, while capsule size was as-
sociated with a higher frequency of recombination (re), the as-
sociation with r/m was not significant in the univariate regres-
sion. Nevertheless, the effect of capsule size and carriage duration
in a multivariate analysis accounts for the high correlation be-
tween the two recombination parameters, i.e., r/m and re, indi-
cating that these two factors are key contributors to the observed
variation. The capsule data used in this study were obtained in
vitro, and the expressed capsule sizes during carriage and trans-
mission remain unclear and should be investigated in follow-up
studies.
The properties of the capsule that we have studied here are also
highly correlated (Pearson correlation coefficients are shown in
Fig. S7 in the supplemental material), and accounting for this
removed the association (Table 2). As a result, we have not been
able to precisely define the underlying causes. A plausible mecha-
nism is that serotypes with larger capsules are more exposed to
other cocolonizing strains because they are carried for a longer
period and at a higher prevalence. One way to test this would be to
use serotype switches as natural experiments and compare r/m
and re between switched lineages where the two serotypes in-
volved vary in their size. However, this is limited by the fact that
serotype switches identified in Fig. 1 and other studies typically
involve serotypes that are effective colonizers such as serogroups
6, 15, 18, 19, and 23 (15). While this means we cannot use the
present data set to do the above analysis, we should note that this
observation is consistent with the suggestion that more com-
monly carried types are more likely to undergo recombination
with each other.
In conclusion, we have shown that in a set of samples from
Malawi containing many different serotypes, there is a linear rela-
tionship between re and r/m and properties of the capsule. In
general, there is evidence that recombination increases with car-
riage duration and polysaccharide capsule size. We have not been
able to pick out the causal roots of this relationship due to the
complexity of the relationships between other important proper-
ties also associated with capsule, but the observation shows con-
clusively that all serotypes are not alike and that serotypes differ in
how recombination has affected their evolution history, which has
been associated with many different responses from drug resis-
tance to vaccine escape. The serotypes observed in settings with a
high burden of carriage and disease, such as sub-Saharan Africa,
are often different from those found in industrialized nations, and
there has been concern that lineages with serotypes targeted by
vaccine such as serotypes 1, 5, and 7F that are relatively invasive,
with a short duration of carriage and small capsules, might survive
a serotype switch (21, 22, 36). The results of this study suggest that
such concerns may be misplaced.
MATERIALS AND METHODS
Isolate collection and genome sequencing. We collected 439 S. pneu-
moniae isolates from the Malawi-Liverpool-Wellcome Trust Clinical Re-
search Programme (MLW) pneumococcal isolate archive in Blantyre,
Malawi. The isolates were routinely collected from patients at the Queen
Elizabeth Central Hospital, a 1,250-bed referral hospital and the largest
hospital located in the Blantyre District in southern Malawi from 2002 to
2011. All isolates were collected before the introduction of the 13-valent
pneumococcal conjugate vaccine (PCV13) in routine childhood immu-
nization programs in Malawi in 2011. Isolates were collected from carriers
(n 75) and patients with invasive disease (n 364) from 2002 to 2011
(see Table S1 in the supplemental material). Isolates were cultured in
Todd-Hewitt broth, and genomic DNA was extracted using the Promega
Wizard DNA genomic DNA purification kit (Promega, USA). DNA se-
quencing was done using the Illumina genome analyzer II (Illumina, CA,
USA) platform at the Wellcome Trust Sanger Institute. A robust bespoke
pipeline (43) that was composed of the Velvet v1.2.09 De Bruijn graph-
based DNA sequence assembler (30), Velvet Optimizer (31), SSPACE
Basic v2.0 contig-scaffolding software (44), GapFiller (45), and SMALT
v0.7.4 short-read aligner (http://sourceforge.net/projects/smalt/) was
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in the figure originated from distinct clades, SC3 and SC9, as shown in Fig. 1
and Table 1.
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used to generate sequence assemblies from the paired-end Illumina se-
quence reads for the study isolates. Serotypes were identified from the
whole-genome sequence data using an in silico approach implemented
with Perl and BioPerl (46) as described by Croucher et al. (47).
Population structure and phylogenetic analysis. Phylogenetic trees
were constructed using a 0.79-Mb sequence alignment of 51,389 single
nucleotide polymorphisms (SNPs) in 852 concatenated core genes pres-
ent in single copies (no paralogs). The conserved (core) and noncon-
served (accessory) genes were identified using the Roary bacterial genome
analysis pipeline (32). The population structure of the isolates was in-
ferred using the hierBAPS module implemented in BAPS v6.0 (33, 34).
Maximum likelihood phylogenies of the concatenated core gene align-
ments for all the study isolates and serotype-specific isolates in the in-
ferred sequence clusters (SCs) from BAPS were constructed using RAxML
v7.0.4 (48). We used a generalized time reversible (GTR) (49) model with
gamma () heterogeneity across nucleotide sites and 100 bootstrap rep-
licates. The tree was rooted with an outgroup clade of nontypeable (NT)
isolates, which form a distinct clade from other pneumococci (50). Phy-
logenetic trees and associated metadata, namely, sequence types (STs),
serotypes, and inclusion of the sample’s serotype in the PCV13 vaccine
formulation, were overlaid on the phylogenies and visualized in iToL (51)
and BioPython scripts (52).
Recombination detection and phylogeny construction. Phylogenies
for specific serotypes were generated for downstream phylogenetic anal-
ysis through mapping paired-end short sequence reads against different
published reference whole-genome sequences (see Table S2 in the supple-
mental material) for different pneumococcal serotypes using SMALT
v0.7.4. The output binary alignment map (BAM) files were realigned us-
ing the Genome Analysis Tool Kit (GATK) v3.3.0 (53). The locations of
recombination events in each chromosome in the alignments were de-
tected using Gubbins v1.1.1 (35). The serotype-specific phylogenies with
recombination removed were constructed using RAxML v7.0.4 (48) as
above and rooted in the middle of the branch, separating the two most
divergent isolates. Visualization of the phylogenies was done as described
in “Population structure and phylogenetic analysis” above.
Carriage duration, serotype invasive potential, and capsule size. We
used previously published data from Kilifi in Kenya, data on carriage
duration of pneumococcal serotypes in the human nasopharynx from
Abdullahi and colleagues (36) and data on serotype invasive potential
(odds ratio for IPD to carriage [ICOR]) from Brueggemann and colleagues
(22). Additional data for serotype 5 invasive potential were obtained from
Smith and colleagues (37). The polysaccharide capsule sizes for the sero-
types were obtained from Weinberger and colleagues (21) where the de-
gree of encapsulation was determined by measuring the zone of exclusion
using the fluorescein isothiocyanate-labeled dextran (FITC-dextran) as-
say. The specific methods used to obtain the data sets are described in the
respective publications. We excluded serotypes with estimated ICOR val-
ues of 0 (22) to prevent overfitting as a consequence of the smaller number
of isolates used from invasive disease sample collection. Genomic data on
the relative recombination rate and frequency of pneumococcal lineages
and prevalence of serotypes in carriage were obtained from Malawi (this
study).
Statistical analysis. We used univariate, multivariable, and multivar-
iate multiple regression to examine the association between known prop-
erties of serotypes and the relative recombination rate (r/m) and fre-
quency (re). The univariate regression model were separately formulated
asYi01xi i for each dependent variableYi(r/m andre) against
each independent variable xi where idesignates the polysaccharide capsule
size, carriage duration, serotype invasive potential, and carriage preva-
lence. The intercept and regression coefficient for the independent vari-
ables are represented by 0 and 1, respectively, while i represents the
residuals. We formulated the multivariable model similarly but included
multiple independent variables to account for collinearity between them
as Yi  0  1xi  2xi  3xi  4xi  i, where 0 represents the
intercept and the terms1,2,3, and4 are the regression coefficients for
each independent variable (xi) where i is polysaccharide capsule size, car-
riage duration, serotype invasive potential and carriage prevalence. We
also modeled the relationship between both dependent variables (r/m
andre) and the independent variables in the multivariable regression this
time with a multivariate multipl e regression model. The multivariate
model was formulated as Ynxm Xnx(p1)(p1)xm nxm, where n des-
ignates each serotype and lineage combination as follows 1-SC2, 5-SC1,
6A-SC3, . . ., and 4-SC13 (Table 1). The m in the matrix Ynxm takes values
1 and 2 that designate dependent variablesr/m andre, respectively. The
model matrix is the term Xnx(p1) and consists of p1 regressors where p
represents polysaccharide capsule size, carriage duration, serotype inva-
sive potential, and carriage prevalence of serotypes. The first column in
the model matrix Xnx(p1) consists of 1s, which represents the regression
constants. The matrix of regression coefficients for all the independent
variables in Xnx(p1) is represented by parameter . The residual term in
the model is represented by the matrix nxm. For comparison with the
multivariable and multivariate analyses, we repeated the univariate anal-
yses with the same sample size.
We calculated the pairwise Pearson correlation coefficients for inde-
pendent and response variables and plotted them using the ggplot2 pack-
age. The regression analysis, normality tests, namely, D’Agostino and
Pearson, Shapiro-Wilk, and Kolmogorov-Smirnov tests, Kruskal-Wallis
and analysis of variance (ANOVA) tests and summary statistics, such as
means and ranges, were calculated using R v3.1.2 (R Core Team, 2014)
and GraphPad Prism v6.0 (GraphPad Software, Inc., CA, USA).
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